MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598104 | Name: BPC-157 free base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BPC 157 is a 15-amino acid fragment of a gastric peptide, BPC, with hepatoprotective effects. BPC 157 is a gut peptide and possesses free radical scavenging activity. This peptide stimulates nitric oxide synthase generation and therefore offers gastric cytoprotection. Unlike other peptides, BPC 157 is effective without a carrier. It participates in muscle healing and is used in the treatment of gastrocnemius muscle complex. BPC 157 is a stable gastric pentadecapeptide that exhibit anti-ulcer and wounds/fistulas healing properties. BPC 157 reduces immediate and delayed damage induced brain trauma and improves nerve regeneration after transection. BPC 157 displays antianxiety and antidepressant effects.

Chemical Structure

BPC-157 free base
BPC-157 free base
CAS#137525-51-0 (free base)

Theoretical Analysis

MedKoo Cat#: 598104

Name: BPC-157 free base

CAS#: 137525-51-0 (free base)

Chemical Formula: C62H98N16O22

Exact Mass: 1418.7042

Molecular Weight: 1419.56

Elemental Analysis: C, 52.46; H, 6.96; N, 15.79; O, 24.79

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
216441-24-6 (sodium) 137525-51-0 (free base) 1628202-16-3 (TFA) 216441-37-1 (acetate)
Synonym
BPC 157; BPC-157; BPC157; Bpc 15; Bpc-15; Bpc15; Booly protection compound 15; BPC 157 TFA; BPC 157 trifluoroacetic acid
IUPAC/Chemical Name
L-Valine, glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-,
InChi Key
HEEWEZGQMLZMFE-RKGINYAYSA-N
InChi Code
InChI=1S/C62H98N16O22/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,50-/m0/s1
SMILES Code
CC(C)[C@@H](C(O)=O)NC([C@H](CC(C)C)NC(CNC([C@H](C)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC([C@H](C)NC([C@H]1N(C([C@H](CCCCN)NC(CNC([C@H]2N(C([C@H]3N(C([C@H]4N(C([C@H](CCC(O)=O)NC(CN)=O)=O)CCC4)=O)CCC3)=O)CCC2)=O)=O)=O)CCC1)=O)=O)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,419.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022 Dec 14;13:1026182. doi: 10.3389/fphar.2022.1026182. PMID: 36588717; PMCID: PMC9794587. 2: Staresinic M, Japjec M, Vranes H, Prtoric A, Zizek H, Krezic I, Gojkovic S, Smoday IM, Oroz K, Staresinic E, Dretar V, Yago H, Milavic M, Sikiric S, Lovric E, Batelja Vuletic L, Simeon P, Dobric I, Strbe S, Kokot A, Vlainic J, Blagaic AB, Skrtic A, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022 Dec 12;10(12):3221. doi: 10.3390/biomedicines10123221. PMID: 36551977; PMCID: PMC9775659. 3: Gamulin O, Oroz K, Coric L, Krajacic M, Skrabic M, Dretar V, Strbe S, Talapko J, Juzbasic M, Krezic I, Lozic M, Stambolija V, Zizek H, Jurca I, Jurjevic I, Blagaic AB, Skrtic A, Seiwerth S, Sikiric P. Fourier Transform Infrared Spectroscopy Reveals Molecular Changes in Blood Vessels of Rats Treated with Pentadecapeptide BPC 157. Biomedicines. 2022 Dec 4;10(12):3130. doi: 10.3390/biomedicines10123130. PMID: 36551886; PMCID: PMC9775416. 4: Sikiric P, Udovicic M, Barisic I, Balenovic D, Zivanovic Posilovic G, Strinic D, Uzun S, Sikiric S, Krezic I, Zizek H, Yago H, Gojkovic S, Smoday IM, Kalogjera L, Vranes H, Sola M, Strbe S, Koprivanac A, Premuzic Mestrovic I, Mestrovic T, Pavic P, Skrtic A, Blagaic AB, Lovric Bencic M, Seiwerth S. Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation. Biomedicines. 2022 Oct 25;10(11):2696. doi: 10.3390/biomedicines10112696. PMID: 36359218; PMCID: PMC9687817. 5: Huang BS, Huang SC, Chen FH, Chang Y, Mei HF, Huang HY, Chen WY, Pang JS. Pentadecapeptide BPC 157 efficiently reduces radiation-induced liver injury and lipid accumulation through Kruppel-like factor 4 upregulation both in vivo and in vitro. Life Sci. 2022 Dec 1;310:121072. doi: 10.1016/j.lfs.2022.121072. Epub 2022 Oct 10. PMID: 36228773. 6: Sikiric P, Gojkovic S, Knezevic M, Tepes M, Strbe S, Vukojevic J, Duzel A, Kralj T, Krezic I, Zizek H, Oroz K, Vranes H, Smoday IM, Kalogjera L, Vlainic J, Kokot A, Jurjevic I, Blagaic AB, Skrtic A, Seiwerth S. Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways. Curr Med Chem. 2023;30(13):1568-1573. doi: 10.2174/0929867329666221005111553. PMID: 36200148. 7: Zemba Cilic A, Zemba M, Cilic M, Strbe S, Ilic S, Vukojevic J, Zoricic Z, Filipcic I, Kokot A, Smoday IM, Rukavina I, Boban Blagaic A, Tvrdeic A, Duplancic B, Stambolija V, Marcinko D, Skrtic A, Seiwerth S, Sikiric P. BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling "Negative-Like" Symptoms of Schizophrenia. Biomedicines. 2022 Jun 21;10(7):1462. doi: 10.3390/biomedicines10071462. PMID: 35884767; PMCID: PMC9313087. 8: Smoday IM, Petrovic I, Kalogjera L, Vranes H, Zizek H, Krezic I, Gojkovic S, Skorak I, Hriberski K, Brizic I, Kubat M, Strbe S, Barisic I, Sola M, Lovric E, Lozic M, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P. Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats. Biomedicines. 2022 Jun 1;10(6):1299. doi: 10.3390/biomedicines10061299. PMID: 35740321; PMCID: PMC9220115. 9: Perovic D, Milavic M, Dokuzovic S, Krezic I, Gojkovic S, Vranes H, Bebek I, Bilic V, Somun N, Brizic I, Skorak I, Hriberski K, Sikiric S, Lovric E, Strbe S, Kubat M, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P. Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy. Curr Issues Mol Biol. 2022 Apr 27;44(5):1901-1927. doi: 10.3390/cimb44050130. PMID: 35678659; PMCID: PMC9164058. 10: Bilic Z, Gojkovic S, Kalogjera L, Krezic I, Malekinusic D, Knezevic M, Sever M, Lojo N, Kokot A, Kasnik K, Kralj T, Vukojevic J, Siroglavic M, Peklic M, Drmic D, Milavic M, Sikiric S, Skorak I, Brizic I, Hriberski K, Kubat M, Vladic J, Boban Blagaic A, Tvrdeic A, Skrtic A, Seiwerth S, Sikiric P. Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide pentadecapeptide BPC 157 in rats with perforated stomach throughout modulation of nitric oxide-system. Comparison with L-arginine, ranitidine and pantoprazole therapy and L-NG-nitro-L-arginine methyl ester worsening. J Physiol Pharmacol. 2021 Dec;72(6). doi: 10.26402/jpp.2021.6.11. Epub 2022 Apr 24. PMID: 35485358. 11: Jung YH, Kim H, Kim H, Kim E, Baik J, Kang H. The anti-nociceptive effect of BPC-157 on the incisional pain model in rats. J Dent Anesth Pain Med. 2022 Apr;22(2):97-105. doi: 10.17245/jdapm.2022.22.2.97. Epub 2022 Mar 25. PMID: 35449779; PMCID: PMC8995671. 12: Barisic I, Balenovic D, Udovicic M, Bardak D, Strinic D, Vlainić J, Vranes H, Smoday IM, Krezic I, Milavic M, Sikiric S, Uzun S, Zivanovic Posilovic G, Strbe S, Vukoja I, Lovric E, Lozic M, Sever M, Lovric Bencic M, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats. Biomedicines. 2022 Jan 26;10(2):265. doi: 10.3390/biomedicines10020265. PMID: 35203478; PMCID: PMC8869603. 13: Tepes M, Gojkovic S, Krezic I, Zizek H, Vranes H, Madzar Z, Santak G, Batelja L, Milavic M, Sikiric S, Kocman I, Simonji K, Samara M, Knezevic M, Barisic I, Lovric E, Strbe S, Kokot A, Sjekavica I, Kolak T, Skrtic A, Seiwerth S, Blagaic AB, Sikiric P. Corrigendum: Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats. Front Pharmacol. 2022 Jan 21;12:844785. doi: 10.3389/fphar.2021.844785. Erratum for: Front Pharmacol. 2021 Dec 13;12:718147. PMID: 35126157; PMCID: PMC8814354. 14: Sikiric P, Skrtic A, Gojkovic S, Krezic I, Zizek H, Lovric E, Sikiric S, Knezevic M, Strbe S, Milavic M, Kokot A, Blagaic AB, Seiwerth S. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J Gastroenterol. 2022 Jan 7;28(1):23-46. doi: 10.3748/wjg.v28.i1.23. PMID: 35125818; PMCID: PMC8793015. 15: Kralj T, Kokot A, Zlatar M, Masnec S, Kasnik Kovac K, Milkovic Perisa M, Batelja Vuletic L, Giljanovic A, Strbe S, Sikiric S, Balog S, Sontacchi B, Sontacchi D, Buljan M, Lovric E, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma. Biomedicines. 2021 Dec 31;10(1):89. doi: 10.3390/biomedicines10010089. PMID: 35052769; PMCID: PMC8773185. 16: Tepes M, Gojkovic S, Krezic I, Zizek H, Vranes H, Madzar Z, Santak G, Batelja L, Milavic M, Sikiric S, Kocman I, Simonji K, Samara M, Knezevic M, Barisic I, Lovric E, Strbe S, Kokot A, Sjekavica I, Kolak T, Skrtic A, Seiwerth S, Boban Blagaic A, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats. Front Pharmacol. 2021 Dec 13;12:718147. doi: 10.3389/fphar.2021.718147. Erratum in: Front Pharmacol. 2022 Jan 21;12:844785. PMID: 34966273; PMCID: PMC8710746. 17: Japjec M, Horvat Pavlov K, Petrovic A, Staresinic M, Sebecic B, Buljan M, Vranes H, Giljanovic A, Drmic D, Japjec M, Prtoric A, Lovric E, Batelja Vuletic L, Dobric I, Boban Blagaic A, Skrtic A, Seiwerth S, Predrag S. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021 Oct 27;9(11):1547. doi: 10.3390/biomedicines9111547. PMID: 34829776; PMCID: PMC8615275. 18: Strbe S, Gojkovic S, Krezic I, Zizek H, Vranes H, Barisic I, Strinic D, Orct T, Vukojevic J, Ilic S, Lovric E, Muzinic D, Kolenc D, Filipčić I, Zoricic Z, Marcinko D, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P. Over-Dose Lithium Toxicity as an Occlusive-like Syndrome in Rats and Gastric Pentadecapeptide BPC 157. Biomedicines. 2021 Oct 20;9(11):1506. doi: 10.3390/biomedicines9111506. PMID: 34829735; PMCID: PMC8615292. 19: Deek SA. BPC 157 as Potential Treatment for COVID-19. Med Hypotheses. 2021 Nov 9;158:110736. doi: 10.1016/j.mehy.2021.110736. Epub ahead of print. PMID: 34798584; PMCID: PMC8575535. 20: Gojkovic S, Krezic I, Vranes H, Zizek H, Drmic D, Batelja Vuletic L, Milavic M, Sikiric S, Stilinovic I, Simeon P, Knezevic M, Kolak T, Tepes M, Simonji K, Strbe S, Nikolac Gabaj N, Barisic I, Oreskovic EG, Lovric E, Kokot A, Skrtic A, Boban Blagaic A, Seiwerth S, Sikiric P. Robert's Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157. Biomedicines. 2021 Sep 23;9(10):1300. doi: 10.3390/biomedicines9101300. PMID: 34680419; PMCID: PMC8533388.

View History

Fluorocoxib D

Fluorocoxib D